D3 Dopamine Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
D3 dopamine receptor neurons (DRD3-expressing neurons) represent a specific population of neurons that express the dopamine D3 receptor subtype. The D3 receptor is a member of the D2-like family of dopamine receptors (D2, D3, D4) and is predominantly expressed in limbic regions associated with reward, motivation, and motor control. These neurons play crucial roles in dopaminergic signaling and are implicated in various neurological and psychiatric disorders, including Parkinson's disease (PD), schizophrenia, and addiction. [1]
The DRD3 gene (Dopamine Receptor D3) is located on chromosome 3q13.3 and encodes a G protein-coupled receptor (GPCR) of the D2-like family. Key features include: [2]
The D3 receptor possesses the classic seven-transmembrane domain structure of GPCRs: [3]
D3 receptor activation triggers multiple intracellular signaling cascades: [4]
D3 receptor-expressing neurons are concentrated in limbic and motor-related structures: [5]
D3 receptors are primarily located on: [6]
D3 receptor neurons exhibit distinct electrophysiological properties: [7]
D3 neurons are central to the brain's reward system:
Though primarily limbic, D3 neurons contribute to motor function:
D3 receptors are critically involved in PD pathophysiology:
The dopamine hypothesis of schizophrenia involves D3 receptors:
D3 neurons play a key role in addictive behaviors:
Targeting D3 receptors offers therapeutic opportunities:
](/cell-types/drd3-gene---drd3-gene-page
--dopamine-receptors---dopamine-receptor-signaling
--nucleus-accumbens---nac-medium-spiny-neurons
--parkinson's-disease---pd-disease-page
--ventral-tegmental-area---vta-neurons
--g-protein-coupled-receptors---gpcr-pathways)## External Links
The study of D3 Dopamine Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Missale, C. et al. (1998) Dopamine receptors: from structure to function. Physiological Reviews, 78(1), 189-225. 1998. ↩︎
Bezard, E. et al. [(2003) Pathophysiology of levodopa-induced dyskinesia in Parkinson's disease. Trends in Neurosciences, 26(8), 391-397](https://doi.org/10.1016/S0166-2236(03). 2003. ↩︎
Heiman, M. et al. (2014) Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia. Proceedings of the National Academy of Sciences, 111(11), 4578-4583. 2014. ↩︎
Kumar, R. et al. (2021) Dopamine D3 receptor as a new therapeutic target for Parkinson's disease. Neuropharmacology, 184, 108361. 2021. ↩︎
Sokoloff, P. et al. (2006) The dopamine D3 receptor and neuropsychiatric diseases. Journal of Neural Transmission, 113(5), 593-595. 2006. ↩︎
[Gurevich, E.V. & Joyce, J.N. (1999) Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology, 20(1), 60-80](https://doi.org/10.1016/S0893-133X(98). 1999. ↩︎
Le Foll, B. et al. (2005) Dopamine D3 receptor ligands for drug addiction treatment: update on recent patents. Recent Patents on CNS Drug Discovery, 1(1), 27-43. 2005. ↩︎